|Celsion Corporation (NASDAQ:CLSN) Jumps 13% On Update of GEN-1|
|By Marilyn Mullen|
|Friday, 20 February 2015 14:52|
Shares of thinly-traded nano cap Celsion Corporation (NASDAQ:CLSN) jumped almost 13% to $3.16 on heavy volume in response to its update on its advancement of GEN-1, its DNA-based immunotherapy, for the front-line treatment of advanced platinum-resistant and recurring ovarian cancer.
The FDA has cleared the Phase 1 dose escalation trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer. The trial should commence at five to six U.S. medical centers by mid-year.
The company presents clinical and preclinical data showing the safety, biological activity and clinical benefits of GEN-1 today at the Molecular Medicine TRI-Conference in San Francisco. In an earlier Phase 1 study, GEN-1 demonstrated a disease control rate (DCR) of 31% and median overall survival (OS) of 18 months. In a Phase 2 study, it demonstrated a DCR of 45% and median OS of 10 months. DCR is the proportion of patients who show a response to treatment.
Celsion Corporation is an oncology drug development company. The company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Its lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. Its pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers.